

EHA2024 – BeiGene Presentations

Abstract Title	Abstract #	Presentation Type	Presenting Author
BTK CDAC (investigational compound)			
Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: Results from the phase 1 BGB-16673-101 study	S157	Oral	R. Parrondo
Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) indolent NHL: Results from the phase 1 BGB-16673-101 study	P1119	Poster	C. Cheah
Sonrotoclax (investigational compound)			
Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro) in combination with zanubrutinib (zanu) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses	S156	Oral	S. Opat
Combination treatment with novel BCL-2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL)	P1112	Poster	C. Tam
Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström's macroglobulinemia	P1110	Poster	C Cheah
Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in treatment-naïve patients with acute myeloid leukemia	P538	Poster	S. Tan
Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia	P562	Poster	P. Montesinos
Sonrotoclax plus dexamethasone is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma harboring t(11;14)	P898	Poster	B. Dhakal
BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia	PB2954	Online abstract	J. Matous
CELESTIAL-TN CLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL	PB2540	Online abstract	P. Patten

Zanubrutinib			
Combination of zanubrutinib + venetoclax for treatment-naïve (TN) CLL/SLL with del(17p) and/or TP53: Preliminary results from SEQUOIA arm D	S160	Oral	P. Ghia
Intra-patient comparative analysis of zanubrutinib plus obinutuzumab efficacy in relapsed/refractory follicular lymphoma using the Growth Modulation Index	P1143	Poster	K. Bouabdallah
Risk of hypertension in patients with CLL/SLL who participated in ALPINE: A post hoc analysis	P1836	ePoster	W. White
Risk of new-onset hypertension in newly diagnosed chronic lymphocytic leukemia patients treated with Bruton tyrosine kinase inhibitors: A real-world study using the Symphony Health Solutions database	P1847	ePoster	W. White
Zanubrutinib vs. acalabrutinib in B-cell malignancies: an adverse event-based economic analysis	S333	Oral	T. Munir
Efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed or refractory chronic lymphocytic leukemia (R/R CLL): A matching-adjusted indirect comparison (MAIC)	P700	Poster	M. Shadman
Efficacy and safety of zanubrutinib vs. venetoclax+ibrutinib in the treatment-naïve (TN) chronic lymphocytic leukemia (CLL): A matching-adjusted indirect comparison (MAIC)	P702	Poster	T. Munir
Matching-adjusted indirect comparison (MAIC) of zanubrutinib versus real-world chemoimmunotherapy (CIT) or chemotherapy (chemo) in relapsed/refractory marginal zone lymphoma (R/R MZL)	P1123	Poster	R. Walewska
Indirect comparison of efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed/refractory mantle cell lymphoma	P2058	ePoster	B. Shah
Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: A network meta-analysis	P701	Poster	M. Shadman
Zanubrutinib vs other Bruton's tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia: A multilevel network meta-regression	P698	Poster	M. Shadman
Patient-reported outcome (PRO)-based recurrent symptomatic deterioration predicts disease progression: Results from the ALPINE trial	P1834	ePoster	J. Brown
Real-world comparative effectiveness of covalent Bruton tyrosine kinase inhibitors (cBTKi) among patients with relapsed/refractory mantle cell lymphoma (R/R MCL)	P1139	Poster	T. Phillips

Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in CLL/SLL	P697	Poster	J. Pinilla-Ibarz
Real-world Bruton tyrosine kinase inhibitor treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in US community oncology practices	P685	Poster	J. Hou
Real-world evaluation of treatment pattern, time to next treatment, healthcare resource utilization, and cost of care in follicular lymphoma	P1124	Poster	S. Gaballa
Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma	P2045	ePoster	B. Shah
Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting	PB2546	Online abstract	D. Andorsky